Holen Sie sich die Stockscreener-App
0.3926
0.93%
0.0036
Schlusskurs vom Vortag:
$0.389
Offen:
$0.39
24-Stunden-Volumen:
43,173
Relative Volume:
0.12
Marktkapitalisierung:
$5.23M
Einnahmen:
$72,100
Nettoeinkommen (Verlust:
$-3.60M
KGV:
-0.3299
EPS:
-1.19
Netto-Cashflow:
$-3.37M
1W Leistung:
+16.98%
1M Leistung:
-11.16%
6M Leistung:
-36.68%
1J Leistung:
-77.04%
1-Tages-Spanne:
$0.3847
$0.40
1-Wochen-Bereich:
$0.3451
$0.40
52-Wochen-Spanne:
$0.325
$2.1608
Silo Pharma Inc Stock (SILO) Company Profile
Firmenname
Silo Pharma Inc
Sektor
Branche
Telefon
(718) 400-9031
Adresse
677 N. WASHINGTON BLVD, SARASOTA
Vergleichen Sie SILO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SILO
SILO PHARMA INC
|
1.71 | 17.96M | 0 | 0 | 0 | 0.00 |
|
MOBBW
Mobilicom Limited Warrants
|
3.65 | 4.83B | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
4.66 | 416.27M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
GOODO
Gladstone Commercial Corporation
|
20.75 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
8.57 | 357.42M | 0 | 0 | 0 | 0.00 |
|
DWLD
Davis Select Worldwide ETF
|
47.51 | 0 | 0 | 0 | 0 | 0.00 |
Silo Pharma Inc Aktie (SILO) Neueste Nachrichten
Weekly Recap: Is Silo Pharma Inc stock a safe haven asset2025 Growth vs Value & Weekly Momentum Picks - moha.gov.vn
Can Silo Pharma Inc. stock sustain institutional interest2025 Macro Impact & Pattern Based Trade Signal System - ulpravda.ru
Why Silo Pharma Inc. stock could be next big winner2025 Earnings Surprises & Weekly High Return Stock Opportunities - ulpravda.ru
Is Silo Pharma Inc. stock a safe haven assetMarket Growth Summary & Daily Volume Surge Trade Alerts - ulpravda.ru
Why Silo Pharma Inc. stock could see breakout soon2025 Momentum Check & Safe Entry Trade Reports - ulpravda.ru
What drives Soligenix Inc DOA0 stock priceMerger & Acquisition Updates & Buy Sell Timing Alerts - Early Times
Sheppard Mullin Advised Vanterra Ventures, Silo Pharma, Celularity And Others In Recent Deals - Mondaq
Silo Pharma (NASDAQ:SILO) Stock Price Down 2.9% – Here’s Why - Defense World
Silo Pharma signs LOI with Allucent for SPC-15 nasal spray clinical trials - Investing.com Nigeria
Silo Pharma Receives Extended Nasdaq Compliance Grace Period - The Globe and Mail
Silo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15 - GlobeNewswire
Silo Pharma receives extension from Nasdaq to regain minimum bid price compliance - Investing.com
Silo Pharma Received Notice of Noncompliance - TradingView — Track All Markets
How Silo Pharma Inc. stock responds to policy changesEconomic Indicators Overview & Small Entry Trading Portfolio - bollywoodhelpline.com
Is Silo Pharma Inc. stock a buy in volatile marketsQuarterly Risk Review & Low Risk Profit Maximizing Plans - Улправда
How Silo Pharma Inc. stock performs in rising dollar environmentJuly 2025 Macro Moves & Free Community Consensus Stock Picks - Улправда
Gains Report: Is Silo Pharma Inc. stock a buy in volatile markets2025 Trading Recap & AI Forecasted Entry and Exit Points - Улправда
Momentum Shift: How geopolitical tensions affect Silo Pharma Inc. stockRecession Risk & Real-Time Chart Pattern Alerts - Улправда
Can Silo Pharma Inc. stock resist market sell offs2025 Earnings Surprises & Daily Entry Point Alerts - Улправда
Why Silo Pharma Inc. stock remains resilientBuy Signal & High Accuracy Trade Signal Alerts - Улправда
Is Silo Pharma Inc. stock a safe investment in uncertain markets2025 Market Sentiment & Stepwise Trade Signal Guides - Улправда
VIX Spike: Is Silo Pharma Inc. stock a safe haven assetQuarterly Market Summary & High Win Rate Trade Tips - moha.gov.vn
Silo Pharma (SILO) CEO Eric Weisblum reports December insider share purchases - Stock Titan
Silo Pharma (NASDAQ:SILO) Stock Price Down 2.8% – What’s Next? - Defense World
How Silo Pharma Inc. stock performs during Fed tightening cycles2025 Top Decliners & Community Verified Trade Alerts - Newser
SILO Pharma (SILO) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Is Silo Pharma Inc a good long term investmentContrarian Investment Ideas & Free Record-Breaking Gains - earlytimes.in
Silo Pharma CEO Weisblum buys $735 in company stock By Investing.com - Investing.com Australia
Silo Pharma CEO Weisblum buys $735 in company stock - Investing.com India
[Form 4] Silo Pharma, Inc. Insider Trading Activity - Stock Titan
Will earnings trigger a reversal in Silo Pharma Inc.Market Risk Report & Smart Investment Allocation Tips - newser.com
Is Silo Pharma Inc. stock attractive for long term wealth buildingEntry Point & Long-Term Safe Return Strategies - newser.com
Is now a turning point for Silo Pharma Inc.July 2025 Analyst Calls & Accurate Intraday Trade Tips - newser.com
Silo Pharma selects Allucent to support PTSD treatment IND submission By Investing.com - Investing.com Nigeria
Evaluating Silo Pharma Inc. with trendline analysisMarket Rally & Weekly Stock Performance Updates - newser.com
Silo Pharma selects Allucent to support PTSD treatment IND submission - Investing.com
Silo Pharma partners with Allucent to support planned FDA Investigational New Drug application for SPC-15 as a therapeutic for PTSD - MarketScreener
Silo Pharma Partners With Allucent To Support Planned FDA Investigational New Drug Application For Spc-15 As A Therapeutic For Ptsd - TradingView
Silo Pharma Partners with Allucent to Support Planned FDA - GlobeNewswire
Can Silo Pharma Inc. stock deliver strong Q4 earningsNew Guidance & Free Safe Entry Trade Signal Reports - newser.com
Will Silo Pharma Inc. rebound enough to break evenExit Point & Weekly Watchlist for Hot Stocks - newser.com
Finanzdaten der Silo Pharma Inc-Aktie (SILO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Silo Pharma Inc-Aktie (SILO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Weisblum Eric | Chief Executive Officer |
Nov 20 '25 |
Buy |
0.37 |
1,000 |
370 |
210,932 |
| Weisblum Eric | Chief Executive Officer |
Nov 21 '25 |
Buy |
0.36 |
1,000 |
365 |
211,932 |
| Weisblum Eric | Chief Executive Officer |
Nov 18 '25 |
Buy |
0.40 |
7,500 |
3,025 |
205,432 |
| Weisblum Eric | Chief Executive Officer |
Nov 19 '25 |
Buy |
0.41 |
4,500 |
1,823 |
209,932 |
| Weisblum Eric | Chief Executive Officer |
May 27 '25 |
Buy |
0.43 |
10,000 |
4,329 |
197,932 |
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):